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Outcome for children with relapsed acute myeloid
leukemia in the Netherlands following initial
treatment between 1980 and 1998: survival after
chemotherapy only?
We report the outcome of Dutch pediatric relapsed
AML patients and focus on patients treated with
chemotherapy alone. Median time from first complete
remission to relapse was nine months. Second complete
remission (CR2) was achieved in 63%. Overall, only 16%
of patients were survivors. When only patients who
achieved CR2 were analyzed, 50% of the patients treat-
ed with allogeneic stem cell transplantation and 24% of
the patients treated with chemotherapy alone, were
long-term survivors.
The prognosis of children with acute myeloid leukemia
(AML) has improved markedly over the last decades with
5-year overall survival rates (5-year pOS) in the most
recent treatment protocols as high as 50-60%.1 In the
Netherlands, children with AML are treated according to
protocols developed by the Dutch Childhood Oncology
Group (DCOG). Since 1980, four protocols for the treat-
ment of childhood AML have been completed, and over-
all survival has improved from 18% to 42%.2,3 Relapse
remains the most frequent cause of treatment failure,
with a cumulative risk of relapse of 30-40% in most pedi-
atric AML studies.1 In the consecutive Dutch AML proto-
cols, the cumulative risk of relapse was 60, 43, 47 and
26% respectively.3 Allogeneic stem cell transplantation
(alloSCT) is generally recommended as part of treatment
of relapsed AML.4 Formal evidence for this recommenda-
tion is lacking, despite evidence of a graft-versus-
leukemia effect in AML. At initial diagnosis of high-risk
AML, alloSCT seems no better than chemotherapy only.4
Therefore, the need for alloSCT in relapsed AML may be
questioned, at least as a general recommendation. 
We studied all Dutch children and adolescents with
AML that were initially diagnosed and treated between
1980 and 1998 and relapsed before 1st January 2007. The
patients were initially treated according to the Dutch
Childhood Oncology Group (DCOG) protocols AML-80,
AML-82, AML-87 and AML-92/94.2,3 We focussed on
patients reported to be alive without disease after treat-
ment with chemotherapy only for their relapse and sum-
marized the relevant literature. Since autologous SCT has
been reported to provide similar results to intensive
chemotherapy, and does not have a graft-versus-
leukemia effect, these patients (n=9) were included in the
chemotherapy only group.5 Most patients were treated
with a reinduction regimen containing cytarabine, most
frequently in combination with an anthracycline and
etoposide.
A total of 113 relapsed AML cases were identified,
with a median time from first complete remission (CR1)
to relapse of nine months (range 1-61 months). Ninety of
these patients were treated with curative intent and CR2
was achieved in 63%. In univariate analysis, sex, age,
WBC, FAB-type and SCT in CR1 were not associated
with achievement of CR2. None of the patients who
failed to achieve remission on first-line treatment when
treated for their initially diagnosed AML (n=11) achieved
CR2, compared to 72% of patients who did achieve CR1
on first-line treatment (χ2 p<0.0001). CR1 duration
(CR1≤1 year or CR1>1 year) correlated significantly with
the probability of achieving CR2 (55 vs. 76%, p=0.04)
and 10-year pOS (13 vs. 30%, p=0.02) in univariate
analysis. The overall 10-year pOS was 16% (standard
error (SE) 3%), with 18 disease-free long-term survivors. 
AlloSCT was performed in 16 out of the 57 CR2
patients, with 8 (50%) long-term survivors. Ten out of
the 41 patients (24%) treated without alloSCT survived.
This comparison is biased by the fact that to be able to
undergo SCT, it is necessary to have a suitable donor, to
maintain CR2 until the SCT and to be in a relatively good
condition. In multivariate analysis using Cox-regression,
we corrected alloSCT in CR2 for time to transplant. In
this analysis of pOS alloSCT was not an independent
favorable prognostic factor (HR=0.56, 95% confidence
interval (CI) 0.26-1.24, p=0.15), as was also the case for
CR1 duration (HR=1.5, 95% CI 0.78-2.88, p=0.23). This
study was limited by its retrospective nature, the diverse
treatment schedules used, and the relatively small num-
ber of patients, especially when prognostic factors were
analyzed. The 10 long-term survivors treated at relapse
without alloSCT (7 chemotherapy only, plus 3 auto-SCT)
did not have unique or similar clinical or cell biological
features and included 6 patients with relapse within 12
months from CR1 (Table 1). Some of these 10 patients
had been treated in the 1990s with relatively intensive
chemotherapy at initial diagnosis. In 10 out of 18 sur-
vivors, late effects of treatment were reported such as
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secondary malignancies, hypogonadotropic hypogo-
nadism and neurological problems. Late effects were
more frequently reported in children who received a SCT
than in children who did not, with 9/12 patients who
were treated with SCT reporting late effects, compared
to 1/6 patients treated with chemotherapy alone (χ2
p=0.019). In the literature, 6 papers describe the outcome
of cohorts of pediatric relapsed AML patients (Table 2).6-
11 Overall probabilities of survival at 2-5 years ranged
from 12% to 34%. Including the patients in this study,
109 relapsed pediatric AML patients treated with
chemotherapy alone were reported in literature and 34 of
these 91 patients were reported as survivors (31%),
which is surprisingly high. However, patient selection
may have occurred, and some patients may not have
received optimal treatment at initial diagnosis according
to current standards. 
Based on these results, we question whether an
alloSCT in CR2 is the only chance of cure for children
with relapsed AML, as is commonly thought.4 A random-
ized clinical trial to prove this has never been performed.
Especially when a matched donor is unavailable, inten-
sive chemotherapy may be preferable over a mismatched
or haplo-identical donor SCT, which is associated with
significant morbidity and mortality.12,13 Currently, howev-
er, it is not known how to identify the patients who do
Table 1. Long-term survivors of pediatric relapsed AML after treatment with chemotherapy alone.
UPN Relapse Age (yr) Sex FAB Cytogenetics Initial SCT in CR1 CR1 Relapse SCT in CR2 Events in CR2 Follow-up (m)
site treatment (m) treatment
1 BM 14.0 f M1 t(3;5) DA No 33 I: AML82 induction Auto No 151
M: araC, dnr
2 BM 9.8 m M3 t(15;17) DA No 27 I: HD araC No No 171
M: araC, 6MP, vcr (5 yrs)
3 CNS 1.0 m M5 Normal I: dnr, vcr, pred No 9 araC i.th. 1x/wk. No No 176
M: araC, vp16, dnr, cyclo Continuation of M (1 yr)
4 BM 4.1 m AUL Complex ALL, later AML80 No 7 I: DAT No No 183
5 BM/skin 1.2 f M5 Unknown AML82 No 4 I: unknown No No 113
M: vp16, cyclo (2 yr)
6 BM/CNS 11.3 f M4 Inv(16) AML82 MSD 10 AML-BFM87 without M No No 208
7 BM 13.2 f M5 Unknown AML87 No 10 I: ADE, pred, cyclo Auto relapse: 
chemotherapy: CR3
8 BM 15.8 f M6 Unknown AML87 No 25 araC, dox, vp16, Auto No 183
6TG, vcr
9 BM 4.8 m M2au Unknown AML87 No 13 I: AIE, intensification HD No No 100
araC and ifos.
M:6TG and LD araC ( 4yr)
10 CNS 3.1 m M5 11q23 abn AML87 No 4 I: araC, vcr, 6MP + RT CNS, No No 92
i.th. araC, pred.
M: 6MP and i.th. araC, pred (3 yr)
UPN: unique patient number; yr: year; FAB: French-American-British; SCT: stem cell transplantation; CR1: first complete remission; CR2: second complete remission;
m: months; BM: bone marrow; CNS: central nervous system; m: male; f: female; DA: daunorubicin and cytarabine; I: induction; M: maintenance; dnr: daunorubicin;
vcr: vincristine; pred: prednisolon; araC: cytarabine, vp16 etoposide; cyclo: cyclophosphamide; MSD: matched sibling donor; HD: high-dose; 6MP: 6-mercaptopurine;
i.th.: intrathecal; DAT: daunorubicin, cytarabine and 6-thioguanine, ADE cytarabine, daunorubicin, etoposide, dox doxorubicin, AIE cytarabine, idarubicin and etopo-
side, ifos ifosfamide, 6TG: 6-thioguanine; LD: low-dose; RT: radiotherapy; Auto: autologous; CR3: third complete remission. 
Table 2. Reports of the outcome of children with relapsed AML.
Initial study (time period) (reference) Time Period Survival Survival with chemotherapy alone
AML-BFM6 1987-1996 5-year pOS 21% 55% (5/9)
CCG-251/213/28617 1979-1989 3-year pOS 12%* Unknown
CCG-28917 1989-1995 3-year pOS 17%* Unknown
CCG-2951** 1997-2001 2-year pOS 24% 62% (8/13)
DCOG AML 80/82/87/9294 1980-1998 10-year pOS 16% 24% (10/41)
LAME 89/919 1988-1998 5-year pOS 33% 100% (3/3)
MRC AML 108 1988-1995 3-year pOS 24% 18% (3/17)
NOPHO AML 88/9311 1998-2003 5-year pOS 34% 44% (8/18)
St. Jude Children's Hospital AML-87/91/9710 1987-2002 5-year pOS 23% 0% (0/17)
pOS: probability of overall survival. *Also included non-remitters. **Pediatric relapsed AML study .
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not need an alloSCT for cure after relapse. Results of the
ongoing International BFM Study Group Pediatric
Relapsed AML protocol, will contribute to this discussion
in the near future. The Dutch and literature data suggest
that randomized studies of the role of alloSCT in sub-
groups of relapsed AML are required. Meanwhile, exper-
imental allogeneic SCT procedures, such as haplo-identi-
cal and mismatched unrelated donor SCT, should be
carefully balanced against the chance of cure by
chemotherapy only in patients in good quality second
complete remission of AML. 
Bianca F. Goemans,1 Rienk Y.J. Tamminga,2,3 Carin M. Corbijn,2
Karel Hählen,2,4 GertJan J.L. Kaspers1,2
1Department Pediatric Oncology/Hematology, VU University
Medical Center, Amsterdam; 2Dutch Childhood Oncology Group
(DCOG), the Hague; 3Department Pediatric
Oncology/Hematology, Beatrix Children’s Hospital, UMCG,
Groningen; 4Department Pediatric Oncology/Hematology, Sophia
Children’s Hospital, Erasmus MC, Rotterdam, the Netherlands
Key words: acute myeloid leukemia, relapse, chemotherapy,
stem cell transplantation
Correspondence: Bianca F. Goemans, MD, PhD, Department 
of Pediatric Oncology-Hematology, VU University Medical Center,
De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Phone: international +31.20.4442420. Fax: international +31.20.
4442422. E-mail: bf.goemans@vumc.nl
Citation: Goemans BF Tamminga RYJ, Korbijn CM, 
Hählen K, Kaspers GJL. Outcome for children with relapsed acute
myeloid leukemia in the Netherlands following initial treatment
between 1980 and 1998: survival after chemotherapy only?
Haematologica 2008; 93:1418-1420. 
doi: 10.3324/haematol.12807.
References
1. Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia:
international progress and future directions. Leukemia
2005;19:2025-9.
2. van der Does-van den Berg A, Hahlen K, Colly LP, Vossen
JM. Treatment of childhood acute nonlymphocytic
leukemia with high-dose cytosine arabinoside, 6-thiogua-
nine, and doxorubicin without maintenance therapy: pilot
study ANLL-80 of the Dutch Childhood Leukemia Study
Group (DCLSG). Pediatr Hematol Oncol 1988;5:93-102.
3. Kardos G, Zwaan CM, Kaspers GJ, de Graaf SS, de Bont
ES, Postma A, et al. Treatment strategy and results in chil-
dren treated on three Dutch Childhood Oncology Group
acute myeloid leukemia trials. Leukemia 2006;19:2063-71.
4. Bierings M, Nachman JB, Zwaan CM. Stem cell transplan-
tation in pediatric leukemia and myelodysplasia: state of
the art and current challenges. Curr Stem Cell Res Ther
2007;2:53-63.
5. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD,
Barnard DR, et al. A comparison of allogeneic bone mar-
row transplantation, autologous bone marrow transplanta-
tion, and aggressive chemotherapy in children with acute
myeloid leukemia in remission. Blood 2001;97:56-62.
6. Stahnke K, Boos J, Bender-Gotze C, Ritter J, Zimmermann
M, Creutzig U. Duration of first remission predicts remis-
sion rates and long-term survival in children with relapsed
acute myelogenous leukemia. Leukemia 1998;12:1534-8.
7. Wells RJ, Adams MT, Alonzo TA, Arceci RJ, Buckley J,
Buxton AB, et al. Mitoxantrone and cytarabine induction,
high-dose cytarabine, and etoposide intensification for
pediatric patients with relapsed or refractory acute
myeloid leukemia: Children’s Cancer Group Study 2951. J
Clin Oncol 2003;21:2940-7.
8. Webb DK, Wheatley K, Harrison G, Stevens RF, Hann IM.
Outcome for children with relapsed acute myeloid
leukaemia following initial therapy in the Medical
Research Council (MRC) AML 10 trial. MRC Childhood
Leukaemia Working Party. Leukemia 1999;13:25-31.
9. Aladjidi N, Auvrignon A, Leblanc T, Perel Y, Benard A,
Bordigoni P, et al. Outcome in children with relapsed acute
myeloid leukemia after initial treatment with the French
Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol
of the French Society of Pediatric Hematology and
Immunology. J Clin Oncol 2003;21:4377-85.
10. Rubnitz JE, Razzouk BI, Lensing S, Pounds S, Pui CH,
Ribeiro RC. Prognostic factors and outcome of recurrence
in childhood acute myeloid leukemia. Cancer 2007;109:
157-63.
11. Abrahamsson J, Clausen N, Gustafsson G, Hovi L,
Jonmundsson G, Zeller B, et al. Improved outcome after
relapse in children with acute myeloid leukaemia. Br J
Haematol 2007;136:229-36.
12. Veys P, Amrolia P, Rao K. The role of haploidentical stem
cell transplantation in the management of children with
haematological disorders. Br J Haematol 2003;123:193-
206.
13. Drobyski WR, Klein J, Flomenberg N, Pietryga D, Vesole
DH, Margolis DA, et al. Superior survival associated with
transplantation of matched unrelated versus one-antigen-
mismatched unrelated or highly human leukocyte antigen-
disparate haploidentical family donor marrow grafts for
the treatment of hematologic malignancies: establishing a
treatment algorithm for recipients of alternative donor
grafts. Blood 2002;99:806-14.
The International Prognostic Scoring System for
Waldenström’s macroglobulinemia is applicable in
patients treated with rituximab-based regimens
Waldenström’s macroglobulinemia (WM) is character-
ized by lymphoplasmacytic bone marrow infiltration and
by production of serum monoclonal IgM.1 This disease
usually follows a relatively indolent course with a medi-
an survival ranging from 60 months to 120 months in dif-
ferent series. However, in some patients the disease may
be more aggressive causing their death within months.1-7
Several analyses have identified variables that may be
associated with a worse prognosis. These include
advanced age, cytopenia(s), hypoalbuminemia, elevated
serum b2-microglobulin, high IgM, poor performance
status, B-symptoms or splenomegaly.1-8
Recently, a multicenter collaborative project was
undertaken which included a large number of previously
untreated, symptomatic patients who required treat-
ment. An International Prognostic Scoring System for
WM (IPSSWM) was formulated based on 5 adverse
covariates: age >65 years, hemoglobin ≥11.5 g/dL,
platelet count ≤100×109/L, b2-microglobulin >3 mg/L
and serum monoclonal protein concentration >70 g/L.
Low risk is defined by the presence of ≤1 adverse variable
except age, high risk by the presence of >2 adverse char-
acteristics and intermediate risk by the presence of 2
adverse characteristics or age >65 years; 5-year survival
rates are 87%, 68% and 36% respectively.9
However, 96% of the patients included in this analy-
sis had received frontline treatment with alkylating
agents or nucleoside analogs. Since rituximab-based reg-
imens are now frequently used as a frontline treatment in
WM patients, we analyzed whether the IPSSWM can be
applied in these patients. 
Ninety-three previously untreated, symptomatic
patients who received treatment either with single agent
rituximab (21 patients) or with the combination of dex-
amethasone, rituximab and cyclophosphamide (72
patients), formed the basis of this analysis. This analysis
was approved by the Institutional Review Board. These
patients were included in two trials reported previous-
